skip to Main Content
2018

Intratumoral G100, a TLR4 agonist, induces anti-tumor immune responses and tumor regression in patients with Merkel cell carcinoma.

Bhatia S, Miller NJ, Lu H, Vandeven NV, Ibrani D, Shinohara M, Byrd D, Parvathaneni U, Kulikauskas RM, Ter Meulen J, Hsu FJ, Koelle DM, Nghiem P

Clin Cancer Res. 2018 Aug 9. pii: clincanres.0469.2018.

PMID: 30093453

View on PubMed - View PDF

Targeting Merkel cell carcinoma by engineered T cells specific to T-antigens of Merkel cell polyomavirus.

Gavvovidis I, Leisegang M, Willimsky G, Miller NJ, Nghiem P, Blankenstein T.

Clin Cancer Res. 2018 Aug 1;24(15):3644-3655.

PMID: 29669806

View on PubMed - View PDF

Circulating cell-free miR-375 as surrogate marker of tumor burden in Merkel cell carcinoma.

Fan K, Ritter C, Nghiem P, Blom A, Verhaegen ME, Dlugosz A, Odum N, Woetmann A, Tothill RW, Hicks RJ, Sand M, Schrama D, Schadendorf D, Ugurel S, Becker JC

Clin Cancer Res. 2018 Jul 30. pii: clincanres.1184.2018.

PMID: 30061360

View on PubMed - View PDF

Circulating cell-free miR-375 as surrogate marker of tumor burden in Merkel cell carcinoma.

Kaiji Fan, Cathrin Ritter, Paul Nghiem, Astrid Blom, Monique E Verhaegen, Andrzej Dlugosz, Niels Odum, Anders Woetmann, Richard W. Tothill, Rodney J. Hicks, Michael Sand, David Schrama, Dirk Schadendorf, Selma Ugurel and Jurgen C Becker

Clin Cancer Res 2018

PMID: 30061360

View on PubMed - View PDF

Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology.

Bichakjian CK, Olencki T, Aasi SZ, Alam M, Andersen JS, Blitzblau R, Bowen GM, Contreras CM, Daniels GA, Decker R, Farma JM, Fisher K, Gastman B, Ghosh K, Grekin RC, Grossman K, Ho AL, Lewis KD, Loss M, Lydiatt DD, Messina J, Nehal KS, Nghiem P, Puzanov I, Schmults CD, Shaha AR, Thomas V, Xu YG, Zic JA, Hoffmann KG, Engh AM.

J Natl Compr Canc Netw. 2018 Jun;16(6):742-774

PMID: 29891526

View on PubMed - View PDF

Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology.

Bichakjian CK, Olencki T, Aasi SZ, Alam M, Andersen JS, Blitzblau R, Bowen GM, Contreras CM, Daniels GA, Decker R, Farma JM, Fisher K, Gastman B, Ghosh K, Grekin RC, Grossman K, Ho AL, Lewis KD, Loss M, Lydiatt DD, Messina J, Nehal KS, Nghiem P, Puzanov I, Schmults CD, Shaha AR, Thomas V, Xu YG, Zic JA, Hoffmann KG, Engh AM.

J Natl Compr Canc Netw. 2018 Jun;16(6):742-774.

PMID: 29891526

View on PubMed - View PDF

The association between geographic location and incidence of Merkel cell carcinoma in comparison to melanoma: An international assessment.

Stang A, Becker JC, Nghiem P, Ferlay J

Eur J Cancer. 2018 May;94:47-60

PMID: 29533867

View on PubMed - View PDF

The association between geographic location and incidence of Merkel cell carcinoma in comparison to melanoma: An international assessment.

Stang A, Becker JC, Nghiem P, Ferlay J.

Eur J Cancer. 2018 May;94:47-60.

PMID: 29533867

View on PubMed - View PDF

Merkel Cell Carcinoma in the Age of Immunotherapy: Facts and Hopes.

Colunga A, Pulliam T, Nghiem P.

Clin Cancer Res. 2018 May 1;24(9):2035-2043.

PMID: 29217527

View on PubMed - View PDF

Clinical Benefit from Tyrosine Kinase Inhibitors in Metastatic Merkel Cell Carcinoma: A Case Series of 5 Patients.

Tarabadkar ES, Thomas H, Blom A, Parvathaneni U, Olencki T, Nghiem P, Bhatia S.

Am J Case Rep 2018; 19:505-511

PMID: 29706615

View on PubMed - View PDF

Clinical Benefit from Tyrosine Kinase Inhibitors in Metastatic Merkel Cell Carcinoma: A Case Series of 5 Patients.

Tarabadkar ES, Thomas H, Blom A, Parvathaneni U, Olencki T, Nghiem P, Bhatia S

Am J Case Rep. 2018 Apr 30;19:505-511.

PMID: 29706615

View on PubMed - View PDF

Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEC.

Becker JC, Stang A, zur Hausen A, Fischer N, DeCaprio JA, Tothill RW, Lyngaa R, Hansen UK, Ritter C, Nghiem P, Bichakjian CK, Ugurel S, Schrama D.

Cancer Immunol Immunother. 2018 Mar;67(3):341-351.

PMID: 29188306

View on PubMed - View PDF

Back To Top